<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514579</url>
  </required_header>
  <id_info>
    <org_study_id>05-DCB</org_study_id>
    <nct_id>NCT00514579</nct_id>
  </id_info>
  <brief_title>Adult Double Cord Blood Transplant Study</brief_title>
  <official_title>A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults With Hematologic Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for International Blood and Marrow Transplant Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center for International Blood and Marrow Transplant Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of the study is double unit umbilical cord blood transplantation in adults
      will be associated with a one year survival rate of at least 40%.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure overall survival of double unit UCBT in adult patients with hematologic malignancies</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure incidence of donor-derived neutrophil and platelet recovery</measure>
    <time_frame>100 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure contribution of each unit to initial and sustained engraftment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure incidence and severity of acute graft-versus-host disease</measure>
    <time_frame>100 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure incidence and severity of chronic GVHD</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure incidence of transplant-related mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure incidence of malignant relapse</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure incidence of serious infectious complications</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure incidence of immune reconstitution</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure probability of overall and disease-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Cord Blood Stem Cell Transplantation</condition>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Myeloablative double unit UCBT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cord blood transplantation</intervention_name>
    <description>Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation</description>
    <arm_group_label>Myeloablative double unit UCBT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 22 - 50 years

          -  Patients will have one of the following hematological malignancies:

               -  Acute myelogenous leukemia (AML): Complete first remission (CR1) at high risk for
                  relapse or Complete second remission (CR2)

               -  Acute lymphoblastic leukemia (ALL): Complete first remission (CR1) at high risk
                  for relapse or Complete second remission (CR2)

               -  Acute undifferentiated leukemia (AUL) or biphenotypic leukemia: CR1 or CR2

               -  Myelodysplastic Syndrome (MDS) with one of the following: Low and Intermediate-1
                  International Prognostic Scoring System (IPSS) score with Life-threatening
                  neutropenia or thrombocytopenia; or Platelet transfusion dependence
                  Intermediate-2 or High IPSS score Therapy-related disease: patient with history
                  of chemotherapy and current evidence of MDS

          -  Patients with adequate organ function and performance status criteria

          -  Two Suitable Umbilical Cord Blood Units: a cryopreserved dose of at least 1.5 x 107
             TNC/kg. If the unit contains red cells at time of cryopreservation, the cryopreserved
             dose must be at least 2.0 x 107 TNC/kg. Each unit must be at least 4/6 HLA-A and B
             antigen, and DRB1 allele matched with the recipient. Each unit must be at least 3/6
             HLA-A, B DRB1 antigen matched to each other.

        Exclusion Criteria:

          -  Patient with suitable related donor

          -  AML, ALL, AUL, biphenotypic leukemia beyond CR2

          -  AML evolved from myelofibrosis

          -  Any acute leukemia with:

               -  Morphologic relapse or persistent disease in the BM

               -  Active extra-medullary leukemia including active CNS leukemia

               -  Requiring greater than two cycles of chemotherapy to obtain present remission
                  status

          -  Bone marrow aplasia (defined as BM cellularity &lt; 5% at transplant work-up)

          -  MDS with 10% or greater bone marrow blasts at pre-transplant workup

          -  Prior autologous or allogeneic HSC transplant at any time

          -  Prior radiation therapy rendering patient ineligible for TBI

          -  Any uncontrolled infection at time of study enrollment

          -  Seropositive or NAT positive for HIV or HTLV1

          -  Females who are pregnant or breast feeding

          -  Patient unable to give informed consent or unable to comply with the treatment
             protocol including appropriate supportive care, follow-up, and research tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliet Barker, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood and Marrow Transplant Program at Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2007</study_first_posted>
  <last_update_submitted>March 7, 2014</last_update_submitted>
  <last_update_submitted_qc>March 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cord Blood Stem Cell Transplantation</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

